KALA — KALA BIO, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1479419 ·
Last close
$0.30
Market Cap
$5.74M
52W High
$95.50
52W Low
$0.29
ADV30
2,988,279
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -1,721,000 | -1,581,000 | 10,582,000 | 229,000 | 1,538,000 |
| Mar 2026 | 0 | — | -1,802,000 | -1,621,000 | 12,318,000 | 1,764,000 | 1,557,000 |
| Dec 2025 | 0 | — | -10,225,000 | 686,000 | 9,490,000 | 7,557,000 | 2,494,000 |
| Sep 2025 | 0 | — | -10,181,000 | -7,564,000 | 25,021,000 | 21,096,000 | 33,686,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-26,062,000
Investing CF
$-7,015,000
Financing CF
$-7,381,000
CapEx
$-69,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-216.49
As of
2026-08-23
Balance + Analyst (yfinance extras)
Retained Earnings
$-696,521,000
Inventory
—
Receivables
$74,000
ST Investments
$7,000,000
EBIT TTM
$-17,469,000
Pretax Income TTM
$-19,654,000
Interest Exp TTM
$2,185,000
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -39,032,000 | -26,980,000 | 9,490,000 | 2,494,000 | 6,996,000 | -31,991,000 |
| Dec 2024 | 0 | -34,235,000 | -38,511,000 | 55,483,000 | 43,151,000 | 12,332,000 | -29,382,000 |
| Dec 2023 | 0 | -34,328,000 | -42,199,000 | 55,949,000 | 48,445,000 | 7,504,000 | -27,927,000 |
| Dec 2022 | 3,892,000 | -81,356,000 | -44,822,000 | 86,820,000 | 67,846,000 | 18,974,000 | -78,908,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$751,000
NetIncome TTM
$-19,654,000
OpCashFlow TTM
—
Assets (Latest)
$12,318,000
Forward EPS
$-6.67
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GELS | Gelteq Ltd | $5.88M | $0.55 | — |
| PULM | Pulmatrix, Inc. | $5.58M | $1.53 | — |
| INBP | INTEGRATED BIOPHARMA INC | $5.90M | $0.19 | — |
| IMNN | Imunon, Inc. | $6.00M | $1.07 | — |
| ACXP | Acurx Pharmaceuticals, Inc. | $5.37M | $1.25 | — |
News headlines (Yahoo Finance, 1h cache)
KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team
2026-09-17 11:30 · Yahoo
Kala Bio Signs Exclusive U.S. Distribution Agreement for Virotek Ophthalmology Genetic Tests
2026-09-03 13:47 · Yahoo
Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
2026-09-03 12:30 · Yahoo
Kala Bio Targets Near-Term Revenue With Virotek Ophthalmology Genetic Testing Partnership
2026-09-01 15:05 · Yahoo
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
2026-09-01 11:45 · Yahoo
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
2026-04-21 11:00 · Yahoo
KALA BIO Announces Reverse Stock Split
2026-05-07 13:00 · Yahoo
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities
2026-04-01 10:45 · Yahoo
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live
2026-03-30 12:45 · Yahoo
KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception
2026-09-29 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.